<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006156</url>
  </required_header>
  <id_info>
    <org_study_id>000189</org_study_id>
    <secondary_id>00-CH-0189</secondary_id>
    <nct_id>NCT00006156</nct_id>
  </id_info>
  <brief_title>Feasibility Study for Development of an Early Test for Ovarian Failure</brief_title>
  <official_title>FSH-Stimulated Inhibin B as a Marker for Early Ovarian Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This purpose of this study is to gain information about normal ovarian function that will be
      useful in developing a test for early detection of ovarian failure. The ovaries produce
      female hormones, such as estrogen, that are important in maintaining a woman's health. When
      the ovaries do not work properly, problems can develop. Unfortunately, there is no test that
      can detect ovarian failure early in its course. By the time premature ovarian failure is
      diagnosed in young women, two-thirds have already developed osteopenia (loss of some bone
      mass) and nearly one in ten have osteoporosis, a greater loss of bone mineral density that
      weakens bones and increases the risk of fractures.

      Women with normal ovarian function ages 18 to 55 and postmenopausal women 60 years of age or
      older may be eligible for this study. Candidates will be screened with a medical history,
      physical examination, blood tests and vaginal ultrasound examination. For the ultrasound
      study, a probe that emits sound waves is inserted into the vagina, and the sound waves are
      converted to form images of the ovaries. The procedure is done with an empty bladder and
      takes about 10 minutes. After this screening visit (Visit 1), those enrolled in the study
      will return to the NIH Clinical Center for the following additional procedures:

      Visit 2-Will be scheduled between days 3 and 5 of the menstrual cycle (for women who are
      still menstruating). Participants will have blood tests to measure hormone levels and to
      check for pregnancy, and will have another transvaginal ultrasound examination. They will
      then receive an injection of a synthetic form of follicle stimulating hormone (FSH), a
      hormone the body makes normally.

      Visits 3 and 4-Will be scheduled 24 and 36 hours after the FSH injection given during Visit 2
      for collection of blood samples.

      Visit 5-Will be scheduled 48 hours after the FSH injection for additional blood sampling and
      a final transvaginal ultrasound examination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot project to test the feasibility of developing an FSH stimulation test. There
      is a need for a sensitive and specific marker to detect ovarian insufficiency early in its
      course. FSH stimulates inhibin B production by the granulosa cells of the cohort of ovarian
      follicles; serum inhibin B in turn participates in the negative feedback loop regulating FSH
      secretion. This protocol is characterizing the normal FSH-stimulated serum inhibin B response
      to a single subcutaneous injection of 300 IU human recombinant FSH given on day 2 to 4 of the
      menstrual cycle. In preliminary analysis under this protocol we have demonstrated that
      FSH-stimulated serum inhibin B levels measured at 24 hours after injection is a more robust
      marker of functional ovarian age than ovarian follicle count by transvaginal ultrasound,
      basal serum Mullerian Inhibiting Substance (MIS) levels, or basal serum FSH levels. Multiple
      regression analysis has revealed that FSH-stimulated inhibin B, FSH-stimulated estradiol, and
      basal FSH contribute significantly to an ability to predict functional ovarian age (as
      approximated by chronological age). The resulting regression equation relating these three
      parameters with age has a correlation coefficient of 0.742 and a coefficient of determination
      of 0.551. The protocol is now evaluating the reproducibility of this test and the feasibility
      of generating normative data in young women between the ages of 18 and 25. The results of
      this study may define parameters that could lead to earlier diagnosis and treatment of
      premature ovarian insufficiency.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Follicle Stimulating Hormone Stimulated Serum Inhibin B Levels.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follicle Stimulating Hormone Stimulated Serum Estradiol (E2) Levels</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Healthy</condition>
  <condition>Premature Ovarian Failure</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control for FSH stimulation test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: FSH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FSH Stimulation Test</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>No injection of FSH</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: FSH</intervention_name>
    <description>FSH Stimulation Test</description>
    <arm_group_label>Drug: FSH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        A. Women with normal ovarian function:

        Age 18 to 55.

        Normal body mass index (18-30 kg/m(2)).

        Normal menstrual cycles (between 25-35 days in length).

        Ovulatory serum progesterone concentrations (in excess of 6 ng/mL in the menstrual cycle
        just preceding the study cycle).

        B. Postmenopausal women (to serve as negative controls):

        Greater than or equal to 60 years of age.

        Proven fertility (as evidenced by a history of pregnancy regardless of outcome).

        Normal body mass index (18-30 kg/m(2)).

        Naturally menopausal: amenorrhea for at least one year; serum FSH greater than 40 IU/mL.

        C. Women carriers of FMR1 premutations:

        Age 18 to 40.

        50 to 200 CGG repeats.

        Normal menstrual cycles (between 25-35 days in length).

        Have previously had genetic counseling regarding their FMR1 status.

        EXCLUSION CRITERIA:

        History of infertility or infertility in a first degree relative.

        Acute or chronic disease.

        Menopause due to surgery, radiation, or chemotherapy.

        Current use of oral contraceptives or hormone replacement therapy, or use of these agents
        within the previous 3 months.

        Use within the previous three months of any medication known to affect the
        hypothalamic-pituitary-ovarian axis (including over-the-counter and alternative medicines).

        History of excessive exercise (greater than 10 hours a week).

        Girls will be excluded because there are no data regarding FSH use in children.

        Smokers.

        Pregnant.

        Breast feeding.

        Persistent ovarian masses.

        History of tumors of the ovary, breast, uterus, hypothalamus, or pituitary.

        History of breast or endometrial cancer.

        History of hypersensitivity to recombinant FSH or any one of its excipients.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Anasti JN, Kalantaridou SN, Kimzey LM, Defensor RA, Nelson LM. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol. 1998 Jan;91(1):12-5.</citation>
    <PMID>9464713</PMID>
  </reference>
  <reference>
    <citation>Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986 Apr;67(4):604-6.</citation>
    <PMID>3960433</PMID>
  </reference>
  <reference>
    <citation>Faddy MJ, Gosden RG. A model conforming the decline in follicle numbers to the age of menopause in women. Hum Reprod. 1996 Jul;11(7):1484-6.</citation>
    <PMID>8671489</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2000</study_first_submitted>
  <study_first_submitted_qc>August 9, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2000</study_first_posted>
  <results_first_submitted>March 28, 2013</results_first_submitted>
  <results_first_submitted_qc>March 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2013</results_first_posted>
  <last_update_submitted>March 28, 2013</last_update_submitted>
  <last_update_submitted_qc>March 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Lawrence Nelson, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ovarian Failure</keyword>
  <keyword>Ovary</keyword>
  <keyword>Aging</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Primary Ovarian Insufficiency(POI)</keyword>
  <keyword>Premature Menopause</keyword>
  <keyword>Premature Ovarian Failure (POF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Drug - FSH</title>
        </group>
        <group group_id="P2">
          <title>Control</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drug - FSH</title>
        </group>
        <group group_id="B2">
          <title>Control</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Follicle Stimulating Hormone Stimulated Serum Inhibin B Levels.</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug - FSH</title>
          </group>
          <group group_id="O2">
            <title>Control</title>
          </group>
        </group_list>
        <measure>
          <title>Follicle Stimulating Hormone Stimulated Serum Inhibin B Levels.</title>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7" spread="3.7"/>
                    <measurement group_id="O2" value="48.8" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" spread="7.9"/>
                    <measurement group_id="O2" value="47.7" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follicle Stimulating Hormone Stimulated Serum Estradiol (E2) Levels</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug - FSH</title>
          </group>
          <group group_id="O2">
            <title>Control</title>
          </group>
        </group_list>
        <measure>
          <title>Follicle Stimulating Hormone Stimulated Serum Estradiol (E2) Levels</title>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" spread="2.0"/>
                    <measurement group_id="O2" value="25.0" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" spread="6.4"/>
                    <measurement group_id="O2" value="28.3" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adverse Events Not Collected</title>
          <description>Adverse Events Not Collected</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nelson, Lawrence Merle</name_or_title>
      <organization>National Institute of Child Health and Human Development</organization>
      <phone>+1 301 402 6608</phone>
      <email>nelsonl@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

